Skip to content

Lakefront Biotherapeutics

US · LKFT #2803 by market cap Listed 1970
33.31 -0.08 -0.24%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:26

Valuation each multiple against its own 5-year range

P/B ratio 0.63 Cheap vs history 27th percentile
5-year average 0.91 · #78 of 515 in Biotechnology
P/E ratio 2.55 In line with history 61st percentile
5-year average 15.34 · forward -21.92 · #16 of 77 in Biotechnology
P/S ratio 2.19 Cheap vs history 16th percentile
5-year average 4.83 · forward 62.69 · #54 of 390 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Lakefront Biotherapeutics (LKFT) 2.18B 2.51 0.62 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value36.38 Economic moatNone UncertaintyHigh

Trading 9.2% below Morningstar's fair value estimate.

Fair value

Lakefront Biotherapeutics NV earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $36.38 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 169.7% lies in the top 20% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 42.6%, a core component of profitability, ranks in the top 10% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 16:26:21 · For reference only, not investment advice and not tailored to your situation.

Lakefront Biotherapeutics discussion 0 comments

Add a comment